Minerva Neurosciences (NERV) Misses Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Minerva Neurosciences Reports Third Quarter 2016 Financial Results and Business Updates
November 3, 2016 7:30 AM EDTWALTHAM, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the third quarter ended September 30, 2016.
Recent highlights for Minerva include the completion and analyses of positive data from the 24-week open label extension phase of our Phase IIb trial with MIN-101 for schizophrenia announced on October 26 and the acceptance of four abstracts for presentation at the 55th Annual Meeting of the American College of... More
